Organoidsciences Ltd (476040) Fair Value & Analysis
Healthcare · KR · Market cap 78.0B KRW
Fair value as of: Jun 24, 2026
Analysis
Organoidsciences Ltd (476040) currently trades at 10,050 KRW, while our model-based Fair Value estimate is 11,234 KRW — implying the stock looks roughly 11.8% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Organoidsciences Ltd (476040) undervalued?
What is the fair value of 476040?
What is the quality score of 476040?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.